In an unusual move for a startup, the cross-border payments company has taken its governance and dividends rights back—for a premium. Read More
Related Articles
How a cheaper, easier-to-make COVID vaccine could lift up the world
Posted on Author admin
How a new COVID vaccine entrant could curb the pandemic in developing nations. Read More
The SoftBank bets that aren’t doing so great
Posted on Author admin
Inside the failure of Katerra and Greensill Read More
A pullback in late-stage valuations
Posted on Author admin
Are the good times over for late-stage valuations? Not yet. Read More